Do analysts rate SKYA or CARL?

Carlsmed has a consensus price target of $19.33, indicating a potential upside of 69.29%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carlsmed 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts rate SKYA or SGHT?

Sight Sciences has a consensus target price of $8.14, indicating a potential upside of 67.57%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sight Sciences 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Do analysts rate PROF or SKYA?

Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 76.21%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PROF or SKYA?

In the previous week, SkyAI, Inc. Common Stock had 1 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for SkyAI, Inc. Common Stock and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SkyAI, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SKYA or RXST?

RxSight has a consensus target price of $9.44, suggesting a potential upside of 77.19%. Given RxSight's stronger consensus rating and higher possible upside, analysts clearly believe RxSight is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93

Does the media refer more to SKYA or RXST?

In the previous week, SkyAI, Inc. Common Stock and SkyAI, Inc. Common Stock both had 3 articles in the media. RxSight's average media sentiment score of 1.46 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SkyAI, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OBIO or SKYA?

Orchestra BioMed presently has a consensus price target of $13.60, suggesting a potential upside of 247.83%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than SkyAI, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orchestra BioMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 SkyAI, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

SkyAI, Inc. Common Stock (SKYA) Competitors

$1.83 +0.06 (+3.39%)

As of 05/29/2026

Compare

SKYA vs. CARL, SGHT, PROF, RXST, and OBIO

Should you buy SkyAI, Inc. Common Stock stock or one of its competitors? MarketBeat compares SkyAI, Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SkyAI, Inc. Common Stock include Carlsmed (CARL), Sight Sciences (SGHT), Profound Medical (PROF), RxSight (RXST), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

How does SkyAI, Inc. Common Stock compare to Carlsmed?

SkyAI, Inc. Common Stock (NASDAQ:SKYA) and Carlsmed (NASDAQ:CARL) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Carlsmed has higher revenue and earnings than SkyAI, Inc. Common Stock. Carlsmed is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkyAI, Inc. Common Stock	$200K	387.25	-$282.50M	-$1.63	N/A
Carlsmed	$50.51M	6.15	-$29.63M	-$2.51	N/A

In the previous week, SkyAI, Inc. Common Stock had 2 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for SkyAI, Inc. Common Stock and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
SkyAI, Inc. Common Stock	Positive
Carlsmed	Positive

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%
Carlsmed	-57.76%	-60.74%	-29.84%

17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. 1.2% of SkyAI, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Carlsmed has a consensus price target of $19.33, indicating a potential upside of 69.29%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Carlsmed beats SkyAI, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Sight Sciences?

SkyAI, Inc. Common Stock (NASDAQ:SKYA) and Sight Sciences (NASDAQ:SGHT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Sight Sciences has a consensus target price of $8.14, indicating a potential upside of 67.57%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Sight Sciences has higher revenue and earnings than SkyAI, Inc. Common Stock. Sight Sciences is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkyAI, Inc. Common Stock	$200K	387.25	-$282.50M	-$1.63	N/A
Sight Sciences	$79.55M	3.32	-$38.43M	-$0.71	N/A

In the previous week, SkyAI, Inc. Common Stock had 2 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for SkyAI, Inc. Common Stock and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.89 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
SkyAI, Inc. Common Stock	Positive
Sight Sciences	Very Positive

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%
Sight Sciences	-46.83%	-52.34%	-28.49%

SkyAI, Inc. Common Stock has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 1.2% of SkyAI, Inc. Common Stock shares are held by company insiders. Comparatively, 30.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sight Sciences beats SkyAI, Inc. Common Stock on 12 of the 16 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Comparatively, 1.2% of SkyAI, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

Profound Medical has higher revenue and earnings than SkyAI, Inc. Common Stock. Profound Medical is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.37	-$42.57M	-$1.24	N/A
SkyAI, Inc. Common Stock	$200K	387.25	-$282.50M	-$1.63	N/A

In the previous week, SkyAI, Inc. Common Stock had 1 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for SkyAI, Inc. Common Stock and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.94 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SkyAI, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 76.21%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Profound Medical beats SkyAI, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to RxSight?

SkyAI, Inc. Common Stock (NASDAQ:SKYA) and RxSight (NASDAQ:RXST) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

SkyAI, Inc. Common Stock has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, RxSight has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

RxSight has higher revenue and earnings than SkyAI, Inc. Common Stock. RxSight is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkyAI, Inc. Common Stock	$200K	387.25	-$282.50M	-$1.63	N/A
RxSight	$127.48M	1.73	-$38.94M	-$1.13	N/A

In the previous week, SkyAI, Inc. Common Stock and SkyAI, Inc. Common Stock both had 3 articles in the media. RxSight's average media sentiment score of 1.46 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SkyAI, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight has a consensus target price of $9.44, suggesting a potential upside of 77.19%. Given RxSight's stronger consensus rating and higher possible upside, analysts clearly believe RxSight is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 1.2% of SkyAI, Inc. Common Stock shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%
RxSight	-36.58%	-17.01%	-15.12%

Summary

RxSight beats SkyAI, Inc. Common Stock on 11 of the 15 factors compared between the two stocks.

How does SkyAI, Inc. Common Stock compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and SkyAI, Inc. Common Stock (NASDAQ:SKYA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, SkyAI, Inc. Common Stock has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

In the previous week, SkyAI, Inc. Common Stock had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for SkyAI, Inc. Common Stock and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.89 beat SkyAI, Inc. Common Stock's score of 0.62 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Overall Sentiment
Orchestra BioMed	Very Positive
SkyAI, Inc. Common Stock	Positive

SkyAI, Inc. Common Stock has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat SkyAI, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 17.2% of SkyAI, Inc. Common Stock shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 1.2% of SkyAI, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Orchestra BioMed presently has a consensus price target of $13.60, suggesting a potential upside of 247.83%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than SkyAI, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SkyAI, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Orchestra BioMed has higher revenue and earnings than SkyAI, Inc. Common Stock. Orchestra BioMed is trading at a lower price-to-earnings ratio than SkyAI, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.99	-$52.70M	-$0.97	N/A
SkyAI, Inc. Common Stock	$200K	387.25	-$282.50M	-$1.63	N/A

Summary

Orchestra BioMed beats SkyAI, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

Get SkyAI, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYA vs. The Competition

Export

Metric	SkyAI, Inc. Common Stock	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$77.45T	$725.34B	$55.95B	$30.05B
Dividend Yield	N/A	2.56%	2.69%	5.33%
P/E Ratio	-1.12	16.12	21.63	26.27
Price / Sales	387.25	8.37	565.57	116.86
Price / Cash	N/A	17.30	43.22	56.84
Price / Book	0.43	4.09	10.55	7.30
Net Income	-$282.50M	$224.05M	$3.56B	$337.27M
7 Day Performance	1.10%	3.72%	2.85%	3.58%
1 Month Performance	2.52%	4.14%	4.59%	5.71%
1 Year Performance	-51.46%	3.90%	37.62%	39.70%

SkyAI, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYA SkyAI, Inc. Common Stock	0.8326 of 5 stars	$1.83 +3.4%	N/A	-51.5%	$77.45T	$200K	N/A	55	News Coverage
CARL Carlsmed	4.133 of 5 stars	$11.29 +3.3%	$19.33 +71.2%	N/A	$297.13M	$50.51M	N/A	100	High Trading Volume
SGHT Sight Sciences	4.2135 of 5 stars	$4.72 -2.9%	$8.31 +76.1%	+31.0%	$264.43M	$77.36M	N/A	210	Positive News Analyst Forecast
PROF Profound Medical	2.0341 of 5 stars	$6.73 -2.3%	$12.00 +78.3%	+30.2%	$250.37M	$16.10M	N/A	150
RXST RxSight	3.3894 of 5 stars	$5.95 -0.8%	$9.44 +58.7%	-64.6%	$248.38M	$134.48M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYA) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SkyAI, Inc. Common Stock (SKYA) Competitors

SKYA vs. CARL, SGHT, PROF, RXST, and OBIO

How does SkyAI, Inc. Common Stock compare to Carlsmed?

Summary

How does SkyAI, Inc. Common Stock compare to Sight Sciences?

Summary

How does SkyAI, Inc. Common Stock compare to Profound Medical?

Summary

How does SkyAI, Inc. Common Stock compare to RxSight?

Summary

How does SkyAI, Inc. Common Stock compare to Orchestra BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYA vs. The Competition

SkyAI, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SkyAI, Inc. Common Stock (SKYA) Competitors

SKYA vs. CARL, SGHT, PROF, RXST, and OBIO

How does SkyAI, Inc. Common Stock compare to Carlsmed?

Which has preferable earnings and valuation, SKYA or CARL?

Does the media favor SKYA or CARL?

Is SKYA or CARL more profitable?

Do institutionals & insiders believe in SKYA or CARL?

Do analysts rate SKYA or CARL?

Summary

How does SkyAI, Inc. Common Stock compare to Sight Sciences?

Do analysts rate SKYA or SGHT?

Which has stronger valuation and earnings, SKYA or SGHT?

Does the media prefer SKYA or SGHT?

Is SKYA or SGHT more profitable?

Which has more risk & volatility, SKYA or SGHT?

Do insiders & institutionals believe in SKYA or SGHT?

Summary

How does SkyAI, Inc. Common Stock compare to Profound Medical?

Do insiders and institutionals believe in PROF or SKYA?

Which has more volatility & risk, PROF or SKYA?

Which has better earnings & valuation, PROF or SKYA?

Does the media prefer PROF or SKYA?

Is PROF or SKYA more profitable?

Do analysts rate PROF or SKYA?

Summary

How does SkyAI, Inc. Common Stock compare to RxSight?

Which has more volatility & risk, SKYA or RXST?

Which has preferable valuation & earnings, SKYA or RXST?

Does the media refer more to SKYA or RXST?

Do analysts prefer SKYA or RXST?

Do institutionals and insiders believe in SKYA or RXST?

Is SKYA or RXST more profitable?

Summary

How does SkyAI, Inc. Common Stock compare to Orchestra BioMed?

Which has more volatility and risk, OBIO or SKYA?

Does the media favor OBIO or SKYA?

Is OBIO or SKYA more profitable?

Do institutionals & insiders hold more shares of OBIO or SKYA?

Do analysts prefer OBIO or SKYA?

Which has preferable earnings and valuation, OBIO or SKYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYA vs. The Competition

SkyAI, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools